Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens

被引:6
作者
Ferretti, Francesca [1 ]
Mackie, Nicola E. [2 ]
Singh, Gurmit Kaur Jagjit [1 ]
Fox, Julie [3 ]
Kaye, Steve [4 ]
McClure, Myra O. [4 ]
Taylor, Graham [4 ]
Boffito, Marta [1 ,4 ]
机构
[1] Chelsea & Westminster Hosp NHS Fdn Trust, Dept HIV, Sexual Hlth, London, England
[2] Imperial Coll Healthcare NHS Trust, Dept HIV Sexual Hlth & Infect, London, England
[3] Guys & St Thomas Hosp NHS Fdn Trust, London, England
[4] Imperial Coll London, Div Infect Dis, London, England
关键词
HIV; Resistance; Low level viremia; Gag; Protease inhibitors; HIV-1-INFECTED PATIENTS; DRUG-RESISTANCE;
D O I
10.1080/25787489.2020.1716159
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To understand the pathogenesis of low level viraemia (LLV) in HIV-infected patients on boosted protease inhibitors (PI/b), we enrolled 34 subjects with a median HIV-RNA 79 copies/mL and followed them for 15 months. Samples for next generation sequencing were collected at three time-points. Two showed resistance-associated mutations (RAMs) in the protease gene, while 95-100% had RAMs in the gag gene, which evolved in approximately a quarter of subjects, suggesting a potential clinical role of these kind of mutations.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 16 条
[1]  
Auyeung K, 2016, CLIN MICROBIOL INFEC, V22
[2]   Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients [J].
De Meyer, Sandra ;
Lathouwers, Erkki ;
Dierynck, Inge ;
De Paepe, Els ;
Van Baelen, Ben ;
Vangeneugden, Tony ;
Spinosa-Guzman, Sabrina ;
Lefebvre, Eric ;
Picchio, Gaston ;
de Bethune, Marie-Pierre .
AIDS, 2009, 23 (14) :1829-1840
[3]   Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study [J].
Dolling, David I. ;
Dunn, David T. ;
Sutherland, Katherine A. ;
Pillay, Deenan ;
Mbisa, Jean L. ;
Parry, Chris M. ;
Post, Frank A. ;
Sabin, Caroline A. ;
Cane, Patricia A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (10) :2339-2343
[4]  
Fun A, 2012, HUMAN IMMUNODEFICIEN, P1
[5]   Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study [J].
Hermans, Lucas E. ;
Moorhouse, Michelle ;
Carmona, Sergio ;
Grobbee, Diederick E. ;
Hofstra, L. Marije ;
Richman, Douglas D. ;
Tempelman, Hugo A. ;
Venter, Willem D. F. ;
Wensing, Annemarie M. J. .
LANCET INFECTIOUS DISEASES, 2018, 18 (02) :188-197
[6]  
Joya C, 2015, CLIN INFECT DIS, V61, P5072
[7]   Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naive Subjects in the CASTLE Study [J].
Lataillade, Max ;
Chiarella, Jennifer ;
Yang, Rong ;
Schnittman, Steven ;
Wirtz, Victoria ;
Uy, Jonathan ;
Seekins, Daniel ;
Krystal, Mark ;
Mancini, Marco ;
McGrath, Donnie ;
Simen, Birgitte ;
Egholm, Michael ;
Kozal, Michael .
PLOS ONE, 2010, 5 (06)
[8]   Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART [J].
Nettles, RE ;
Kieffer, TL ;
Kwon, P ;
Monie, D ;
Han, YF ;
Parsons, T ;
Cofrancesco, J ;
Gallant, JE ;
Quinn, TC ;
Jackson, B ;
Flexner, C ;
Carson, K ;
Ray, S ;
Persaud, D ;
Siliciano, RF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (07) :817-829
[9]   Future technologies for monitoring HIV drug resistance and cure [J].
Parikh, Urvi M. ;
McCormick, Kevin ;
van Zyl, Gert ;
Mellors, John W. .
CURRENT OPINION IN HIV AND AIDS, 2017, 12 (02) :182-189
[10]  
Perrier M, 2019, J ANTIMICROB CHEMOTH, V74, P1